Project Details
Description
ABSTRACT:
Immunotherapies produce remarkable, long-term responses in subsets of patients with non-small cell lung
cancer, but unfortunately, most patients do not respond to such treatment. Current biomarkers to predict which
patients will benefit have limited accuracy, and decisions to continue or suspend treatment are mainly guided by
monitoring of radiographic changes in tumor size. However, unusual immune-related response patterns such
as pseudo-progression, mixed response, and delayed response can make scans difficult to interpret. Circulating
tumor DNA (ctDNA) has emerged as a highly promising biomarker for monitoring immunotherapy efficacy.
Several studies involving various immunotherapy agents and multiple types of cancer have demonstrated that
early reduction in ctDNA levels during treatment are predictive of tumor response and improved survival
outcomes. However, existing technologies that measure ctDNA by probing for common somatic mutations will
fail patients whose tumors lack these mutations. This limitation is being addressed by creating customized
assays based on patient-specific tumor mutation profiles; but this approach is complex, expensive, and slow.
We have developed a ctDNA assay technology based on detection of epigenetic features that are found in
virtually all cancer cell genomes. Preliminary data indicate that our approach has broad patient coverage and
can be applied to multiple types of cancer without requiring tumor profiling and assay customization. As proof
of concept, we aim to establish the utility of our assay technology for monitoring of lung cancer immunotherapy
response. In this Phase I SBIR application, we will evaluate the analytical and baseline clinical performance
characteristics of the assay technology, with a plan for a larger follow-on clinical utility study in Phase II. The
analytical validation and baseline clinical performance metrics will be benchmarked against existing commercial
mutation-based ctDNA assays to justify further development and commercialization of our technology.
Status | Finished |
---|---|
Effective start/end date | 9/1/23 → 2/29/24 |
Funding
- National Cancer Institute: $398,040.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.